Viewing Study NCT00616057


Ignite Creation Date: 2025-12-24 @ 6:56 PM
Ignite Modification Date: 2026-01-02 @ 6:47 AM
Study NCT ID: NCT00616057
Status: COMPLETED
Last Update Posted: 2012-07-06
First Post: 2008-02-04
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Evaluation of Fructans Supplementation on Parameters of Metabolic Syndrome
Sponsor: Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Organization:

Study Overview

Official Title: Evaluation of Fructans Supplementation on Parameters of Metabolic Syndrome
Status: COMPLETED
Status Verified Date: 2012-07
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: FRUCTOB
Brief Summary: Obesity is constantly increasing, causing an important risk to develop diseases such as heart disease, diabetes,... Some recent studies have shown that obese people present modifications of colon microflora and a low-grade inflammation.

In our laboratory, we have demonstrated that the intake of fructans lessens dietary intake, body weight gain, adipose tissue accumulation and steatosis in rodents. These effects lead to an improvement of insulin resistance and hyperglycemia in diabetic rats and mice. Fructans are also able to restore the microflora disturbed by a high fat diet and to prevent endotoxemia. Moreover, studies have shown that fructans intake promotes satiety (Cani et al, Diabetes 2007) and or decreases fat mass (Abrams et al, Journal of Pediatrics 2007) in healthy human. An intervention study in obese patients is thus needed to study the effects of fructans in the target population.
Detailed Description: None

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?:

Secondary ID Infos

Secondary ID Type Domain Link View
B40320072930 None None View